The first drug fully generated by artificial intelligence entered clinical trials with human patients this week.
"It is the first fully generative AI drug to reach human clinical trials, and specifically Phase II trials with patients," Alex Zhavoronkov, founder and CEO of Insilico Medicine, told CNBC.
"While there are other AI-designed drugs in trials, ours is the first drug with both a novel AI-discovered target and a novel AI-generated design."
One is a Covid-19 drug in phase one clinical trials, and the other is a cancer drug, specifically a "USP1 inhibitor for the treatment of solid tumors," that recently received FDA approval to initiate clinical trials.
"I never imagined in those early days that I would be taking my own AI drugs into clinical trials with patients.
Persons:
Alex Zhavoronkov, Zhavoronkov, Insilico
Organizations:
Insilico, National Institutes of Health, CNBC
Locations:
Hong Kong, U.S, China